Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Consensus Target Price of $38.33 According to Brokerages

Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) have earned a consensus rating of “Buy” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $38.33.

Several research analysts recently commented on the company. Leerink Partners set a $32.00 price target on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, September 18th. Guggenheim restated a “buy” rating and set a $43.00 price objective on shares of Eloxx Pharmaceuticals in a research note on Monday, August 24th. Weiss Ratings assumed coverage on Eloxx Pharmaceuticals in a research note on Friday, August 14th. They set a “sell (d)” rating for the company. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Finally, Lifesci Capital started coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price on the stock.

Eloxx Pharmaceuticals Trading Up 1.1%

NASDAQ:ELOX opened at $13.89 on Tuesday. The firm has a 50-day moving average price of $16.71. The stock has a market cap of $56.12 million, a PE ratio of -9.02 and a beta of -1,960.42. Eloxx Pharmaceuticals has a 1-year low of $8.20 and a 1-year high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. These mutations can cause cells to stop producing functional proteins, potentially leading to serious inherited disorders.

The company’s lead program, ELX-02, was a synthetic aminoglycoside designed to promote ribosomal read-through of premature stop signals in messenger RNA. Eloxx evaluated ELX-02 in clinical development for genetic conditions including cystinosis and explored its potential in other diseases involving nonsense mutations.

Eloxx also developed ZKN-013, an oral small-molecule program intended to address nonsense-mutation disorders.